WRAL Tech Wire

 Tech earnings: Pozen, DexOne, Biocryst, Furiex, Targacept

It's been a busy earnings week, and five North Carolina firms all reported losses.

 Losers in Treximet patent decision are appealing

A securities filing by patent-holder Pozen says that generic drug-makers are appealing a ruling by a judge in that Pozen had exclusive rights to Treximet.

 Pozen names exec for customer development

The Chapel Hill-based pharmaceutical firm looks to boost its own pipeline of products.

 What a relief - Pozen prevails in patent fight

Pozen had sued the Par, Alphapharm and Dr. Reddy's claiming that those generic product infringe on its three migraine drug patents. The litigation was consolidated into one suit that was tried last October.

 Pozen forms advisory board for thoughts on digital development

The Chapel Hill-based pharmaceutical firm is seeking advice about how to revolutionize drug industry marketing and development.

 Semiconductor Research Corp., UCLA develop money-saving chip monitoring process; Pozen ranks high for efficiency; UNC's Thorp headlines medical device event

 Pozen, AstraZeneca sue to block generic version of pain reliever

 Pozen secures preliminary injunction against generic producer

The court order bars Par Pharmaceutical from producing a version of Pozen's Treximet, which is sold by GlaxoSmithKline.

 Pozen licenses migraine drug to J&J subsidiary

 Pozen seeks to block generic version of its pain reliever

 $25M milestone payment lifts Pozen to profitability

The Chapel Hill-based drug development firm reports a positive fourth quarter and full year financials.

 Pozen hits 52-week low on patent news

Shares in Pozen took a hit Thursday after the Chapel Hill-based company failed to win an extension of exclusivity for pediatric use of its migraine drug Treximet.

 Pozen names former Biogen exec to lead sales and marketing

 Pozen to receive $25M payment from AstraZeneca

 Pozen lands $730,000 in federal grants for three drugs

The Chapel Hill firm receives the funds under law that focuses on providing incentives for new drugs.

 Drug firm Pozen loses $8.6 million in third quarter

 Hot Off the Wire: Pozen drug gets EU approval; Classroom software meets national standards; Adobe climbs on Microsoft report

 Pozen reports higher sales, profit in second quarter

 Drug approval triggers a $20 million payday for Pozen

The Chapel Hill-based pharmaceutical firm could receive another $25 million if the pain reliever developed in partnership with AstraZeneca is approved for sale in Europe.

 Oh what a relief – FDA OK means $20M payday for Pozen

Pozen and its partner AstraZeneca can sell Vimovo, which combines a painkiller with the main ingredient in the ulcer medicine Nexium.